This is genuis if it could be put to work. Many possible vaccines for covid-19 are discussed in this paper [0] which is surprisingly accessible. There's a tabl

This is genuis if it could be put to work. Many possible vaccines for covid-19 are discussed in this paper [0] which is surprisingly accessible. There's a table [1] that depicts categorization of vaccine candidates and it does mention attenuated virus as a possible solution, the one in development by Codagenix and The Serum Institute of India [2] expected in the second-quarter of 2022. 2022 seems to be an eternity away, and the problems, as the paper points out, with attenuated vaccines are: 1. Requirement of a much wider phase 3 trial than other vaccine types. 2. Very time consuming to create such viral strains in the lab. There are overwhelming advantages working in its favour, though: 1. Human vaccines using the same platform exist for other diseases. 2. Existing infrastructure can be used to ramp up trials, approvals, manufacturing, and administration. The proposed solution by Dr. Daniel Tillett here makes sense because it turns those disadvantages on its head-- a substantial number of people might already have been infected with proven mild inflection and the strain(s) can be isolated at a much faster clip! [0] https://www.cell.com/immunity/fulltext/S1074-7613(20)30120-5 https://www.cell.com/immunity/fulltext/S1074-7613(20)30120-5 [1] https://www.cell.com/action/showFullTableHTML?isHtml=true&tableId=tbl1&pii=S1074-7613%2820%2930120-5 https://www.cell.com/action/showFullTableHTML?isHtml=true&ta... [2] https://seruminstitute.com/news.php https://seruminstitute.com/news.php